JP2018519508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519508A5 JP2018519508A5 JP2017562628A JP2017562628A JP2018519508A5 JP 2018519508 A5 JP2018519508 A5 JP 2018519508A5 JP 2017562628 A JP2017562628 A JP 2017562628A JP 2017562628 A JP2017562628 A JP 2017562628A JP 2018519508 A5 JP2018519508 A5 JP 2018519508A5
- Authority
- JP
- Japan
- Prior art keywords
- gitr
- time point
- seq
- tumor
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170579P | 2015-06-03 | 2015-06-03 | |
| US62/170,579 | 2015-06-03 | ||
| PCT/US2016/035514 WO2016196792A1 (en) | 2015-06-03 | 2016-06-02 | Anti-gitr antibodies for cancer diagnostics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519508A JP2018519508A (ja) | 2018-07-19 |
| JP2018519508A5 true JP2018519508A5 (enExample) | 2019-06-27 |
| JP6812364B2 JP6812364B2 (ja) | 2021-01-13 |
Family
ID=56194564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562628A Expired - Fee Related JP6812364B2 (ja) | 2015-06-03 | 2016-06-02 | 癌診断用抗ｇｉｔｒ抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10690674B2 (enExample) |
| EP (1) | EP3304079B1 (enExample) |
| JP (1) | JP6812364B2 (enExample) |
| CN (1) | CN107743586B (enExample) |
| BR (1) | BR112017025297A2 (enExample) |
| CA (1) | CA2988115A1 (enExample) |
| EA (1) | EA201792497A1 (enExample) |
| ES (1) | ES2810856T3 (enExample) |
| MX (1) | MX2017015260A (enExample) |
| WO (1) | WO2016196792A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| EP3304079B1 (en) | 2015-06-03 | 2020-06-03 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| EP3325512B1 (en) | 2015-07-23 | 2023-09-06 | Inhibrx, Inc. | Multivalent and multispecific gitr-binding fusion proteins |
| EP3365371B1 (en) | 2015-10-22 | 2025-10-08 | Ablynx NV | Gitr agonists |
| US10281374B2 (en) * | 2015-11-04 | 2019-05-07 | Diagnostic Biosystems | Method of pretreatment of biological samples for an analyte-staining assay method |
| MX2018006072A (es) | 2015-11-19 | 2018-08-01 | Squibb Bristol Myers Co | Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos. |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US11198735B2 (en) * | 2017-03-03 | 2021-12-14 | Rinat Neuroscience Corp. | Anti-GITR antibodies and methods of use thereof |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| CA3057744A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-cd25 antibody-drug conjugate |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| WO2018213297A1 (en) | 2017-05-16 | 2018-11-22 | Bristol-Myers Squibb Company | Treatment of cancer with anti-gitr agonist antibodies |
| KR102442736B1 (ko) | 2017-06-14 | 2022-09-16 | 에이디씨 테라퓨틱스 에스에이 | 항-cd19 adc의 투여를 위한 투약량 체제 |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| WO2018234879A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| MX2019015885A (es) | 2017-06-22 | 2020-09-10 | Novartis Ag | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas. |
| CN111050791A (zh) | 2017-06-27 | 2020-04-21 | 诺华股份有限公司 | 用于抗tim-3抗体的给药方案及其用途 |
| WO2019018730A1 (en) | 2017-07-20 | 2019-01-24 | Novartis Ag | DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF |
| EP3685166A2 (en) * | 2017-09-20 | 2020-07-29 | Mersana Therapeutics, Inc. | Compositions and methods for predicting response to napi2b-targeted therapy |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| CN110357958A (zh) | 2018-03-26 | 2019-10-22 | 信达生物制药(苏州)有限公司 | 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用 |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| JP2021531306A (ja) | 2018-07-25 | 2021-11-18 | アドバンスド アクセラレーター アプリケーションズ エスエー | 神経内分泌腫瘍の処置の方法 |
| EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| US20220056123A1 (en) | 2018-12-21 | 2022-02-24 | Novartis Ag | Use of il-1beta binding antibodies |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| US20220025036A1 (en) | 2018-12-21 | 2022-01-27 | Novartis Ag | Use of il-1beta binding antibodies |
| JP2022516850A (ja) | 2018-12-21 | 2022-03-03 | ノバルティス アーゲー | 骨髄異形成症候群の治療又は予防におけるＩＬ－１β抗体の使用 |
| CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3924054B1 (en) | 2019-02-15 | 2025-04-02 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2021079195A1 (en) | 2019-10-21 | 2021-04-29 | Novartis Ag | Tim-3 inhibitors and uses thereof |
| CN114786679A (zh) | 2019-10-21 | 2022-07-22 | 诺华股份有限公司 | 具有维奈托克和tim-3抑制剂的组合疗法 |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| US20230057071A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
| EP4090335A1 (en) | 2020-01-17 | 2022-11-23 | Novartis AG | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| EP4168007A1 (en) | 2020-06-23 | 2023-04-26 | Novartis AG | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| CN116601713A (zh) * | 2020-09-12 | 2023-08-15 | 阿斯利康(英国)有限公司 | 用于抗her2抗体-药物缀合物疗法的评分方法 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CA3259975A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US7247302B1 (en) | 1996-08-02 | 2007-07-24 | Bristol-Myers Squibb Company | Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| DK0920505T3 (da) | 1996-08-16 | 2008-09-08 | Schering Corp | Pattedyrcelleoverfladeantigener og tilhörende reagenser |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| WO2001040464A1 (en) | 1999-11-30 | 2001-06-07 | Genentech, Inc. | Interleukin-1-receptor associated kinase-3 (irak3) and its use in promotion or inhibition of angiogenesis and cardiovascularization |
| GB9625074D0 (en) | 1996-12-02 | 1997-01-22 | Pharmacia & Upjohn Spa | Receptor belonging to the TNF/NGF receptor family |
| CA2308114A1 (en) | 1997-10-21 | 1999-04-29 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
| WO1999025834A1 (en) | 1997-11-18 | 1999-05-27 | Genentech, Inc. | Dna19355 polypeptide, a tumor necrosis factor homolog |
| JP2002502607A (ja) | 1998-02-09 | 2002-01-29 | ジェネンテク・インコーポレイテッド | 新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸 |
| AU5124699A (en) | 1998-07-22 | 2000-02-14 | Incyte Pharmaceuticals, Inc. | Molecules associated with cell proliferation |
| CA2348157A1 (en) | 1998-12-01 | 2000-06-08 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| KR100529270B1 (ko) | 1998-12-01 | 2005-11-21 | 제넨테크, 인크. | 혈관신생 및 심혈관형성의 촉진 또는 억제 |
| AU3860100A (en) | 1999-02-24 | 2000-09-14 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
| ATE376837T1 (de) | 1999-07-12 | 2007-11-15 | Genentech Inc | Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen |
| ES2387394T3 (es) | 1999-12-23 | 2012-09-21 | Zymogenetics, Inc. | Procedimiento de tratamiento de la inflamación |
| RU2279441C2 (ru) | 1999-12-23 | 2006-07-10 | Займодженетикс, Инк. | Выделенный растворимый il-20 рецептор (варианты) |
| CA2402525A1 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| AU2001274888A1 (en) | 2000-05-19 | 2001-12-03 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| ATE333888T1 (de) | 2000-09-15 | 2006-08-15 | Zymogenetics Inc | Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen |
| JP4009535B2 (ja) | 2001-03-09 | 2007-11-14 | ザイモジェネティクス，インコーポレイティド | 可溶性ヘテロダイマーサイトカイン受容体 |
| WO2003006058A1 (en) | 2001-07-12 | 2003-01-23 | Wyeth | Cd25+ differential markers and uses thereof |
| AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
| WO2004024076A2 (en) | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
| AU2003298607B9 (en) | 2002-10-29 | 2011-08-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1572116A4 (en) | 2002-11-26 | 2007-12-12 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| AU2004244626A1 (en) | 2003-05-23 | 2004-12-09 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof |
| EP1660126A1 (en) | 2003-07-11 | 2006-05-31 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1697418A2 (en) | 2003-11-21 | 2006-09-06 | ZymoGenetics, Inc. | Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| CN101072578A (zh) | 2004-10-29 | 2007-11-14 | 南加州大学 | 用共刺激分子的联合癌症免疫疗法 |
| US20060099171A1 (en) | 2004-11-05 | 2006-05-11 | Masahide Tone | Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells |
| AU2006206343A1 (en) * | 2005-01-19 | 2006-07-27 | Genzyme Corporation | GITR antibodies for the diagnosis of NSCLC |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| JP4984160B2 (ja) | 2005-06-07 | 2012-07-25 | 国立大学法人 東京大学 | 抗体の作製方法 |
| WO2007002223A2 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| WO2007120368A2 (en) | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| JP2008278814A (ja) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用 |
| KR20080105674A (ko) | 2007-05-31 | 2008-12-04 | 울산대학교 산학협력단 | 항-마우스 ｇｉｔｒｌ 단일클론 항체 또는 항-인간ａｉｔｒｌ 단일클론 항체 및 이를 유효성분으로 함유하는염증성 장질환의 예방 및 치료용 조성물 |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| MX2010008578A (es) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc. |
| JP5425180B2 (ja) | 2008-03-27 | 2014-02-26 | ザイモジェネティクス， インコーポレイテッド | ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法 |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| US8993524B2 (en) | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US20130108623A1 (en) | 2010-03-29 | 2013-05-02 | Zymeworks Inc | Antibodies with Enhanced or Suppressed Effector Function |
| EP2598530A2 (en) | 2010-07-29 | 2013-06-05 | Xencor, Inc. | Antibodies with modified isoelectric points |
| WO2012087928A2 (en) | 2010-12-20 | 2012-06-28 | The Rockefeller University | Modulating agonistic tnfr antibodies |
| US20130323259A1 (en) | 2011-01-17 | 2013-12-05 | Novo Nordisk A/S | Il-21 ligands |
| US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| WO2013107413A1 (zh) * | 2012-01-19 | 2013-07-25 | 中国科学院上海巴斯德研究所 | 磷酸化途径相关因子在调控调节性t细胞功能中的应用 |
| AR091116A1 (es) | 2012-05-22 | 2015-01-14 | Bristol Myers Squibb Co | Anticuerpos biespecificos y sus metodos de uso |
| KR101566539B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도 |
| SMT201900242T1 (it) | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| CN107172880B (zh) | 2014-03-24 | 2021-09-28 | 癌症研究技术有限公司 | 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途 |
| LT3148579T (lt) | 2014-05-28 | 2021-05-25 | Agenus Inc. | Anti-gitr antikūnai ir jų panaudojimo būdai |
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| EP3304079B1 (en) | 2015-06-03 | 2020-06-03 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| MX2018006072A (es) | 2015-11-19 | 2018-08-01 | Squibb Bristol Myers Co | Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos. |
| WO2018213297A1 (en) | 2017-05-16 | 2018-11-22 | Bristol-Myers Squibb Company | Treatment of cancer with anti-gitr agonist antibodies |
-
2016
- 2016-06-02 EP EP16731700.7A patent/EP3304079B1/en not_active Not-in-force
- 2016-06-02 EA EA201792497A patent/EA201792497A1/ru unknown
- 2016-06-02 WO PCT/US2016/035514 patent/WO2016196792A1/en not_active Ceased
- 2016-06-02 US US15/578,874 patent/US10690674B2/en active Active
- 2016-06-02 CN CN201680032362.6A patent/CN107743586B/zh not_active Expired - Fee Related
- 2016-06-02 BR BR112017025297-0A patent/BR112017025297A2/pt not_active Application Discontinuation
- 2016-06-02 MX MX2017015260A patent/MX2017015260A/es unknown
- 2016-06-02 CA CA2988115A patent/CA2988115A1/en not_active Abandoned
- 2016-06-02 ES ES16731700T patent/ES2810856T3/es active Active
- 2016-06-02 JP JP2017562628A patent/JP6812364B2/ja not_active Expired - Fee Related
-
2020
- 2020-05-08 US US16/870,006 patent/US11408889B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112703012A (zh) | 治疗癌症的方法 | |
| RU2017116847A (ru) | Антитела к pd-1 | |
| NZ716369A (en) | Anti-ox40 antibodies and methods of using the same | |
| Stevenson et al. | The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia | |
| JP2015533788A5 (enExample) | ||
| JP2020522261A5 (enExample) | ||
| US20180250338A1 (en) | Tumor infiltrating lymphocytes for treatment of cancer | |
| JP2018502828A (ja) | Ｐｄ−１遮断による免疫療法の癌奏効の決定因子 | |
| RU2012109004A (ru) | Антитело против смет и его применение для определения и диагностики рака | |
| JP2018527884A5 (enExample) | ||
| JP2017518366A5 (enExample) | ||
| AU2015265870A1 (en) | PD-L1 antibodies and uses thereof | |
| JP6530391B2 (ja) | Ｃｄ６結合パートナーの使用およびそれに基づく方法 | |
| JP2022524216A (ja) | 持続的臨床効果のがんバイオマーカー | |
| EA201492105A1 (ru) | Иммунотерапия злокачественных опухолей путем нарушения передачи сигналов pd-1/pd-l1 | |
| JP2015530868A5 (enExample) | ||
| CN115087749A (zh) | 用于通过分析循环肿瘤dna进行分子疾病评定的方法和系统 | |
| JP2017501143A5 (enExample) | ||
| TW202028251A (zh) | 抗原結合分子和使用彼之方法 | |
| JP2020510409A5 (enExample) | ||
| JP2014523920A5 (enExample) | ||
| JP2016502091A5 (enExample) | ||
| JP2023526044A5 (enExample) | ||
| WO2025042607A1 (en) | Modulation of pglyrp1 for treatment of cancer and autoimmunity | |
| US10584387B2 (en) | Detection of hepatitis delta virus (HDV) for the diagnosis and treatment of Sjögren's syndrome and lymphoma |